Barclays Begins Coverage on Insmed (NASDAQ:INSM)

Research analysts at Barclays assumed coverage on shares of Insmed (NASDAQ:INSM) in a research note issued on Tuesday, Marketbeat reports. The firm set an “overweight” rating and a $231.00 price target on the biopharmaceutical company’s stock. Barclays‘s price objective would suggest a potential upside of 48.18% from the stock’s current price.

Several other research firms also recently weighed in on INSM. Morgan Stanley set a $157.00 target price on shares of Insmed in a report on Thursday, January 8th. Roth Mkm raised shares of Insmed to a “strong-buy” rating in a research note on Friday, January 23rd. Royal Bank Of Canada upped their target price on Insmed from $197.00 to $200.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Evercore ISI reissued an “outperform” rating and set a $180.00 price target on shares of Insmed in a research report on Wednesday, October 1st. Finally, Citigroup restated an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $205.83.

Insmed Stock Down 4.2%

INSM opened at $155.89 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. The company has a market cap of $33.25 billion, a price-to-earnings ratio of -25.18 and a beta of 1.08. Insmed has a one year low of $60.40 and a one year high of $212.75. The business’s fifty day moving average is $181.91 and its two-hundred day moving average is $157.83.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The firm had revenue of $142.34 million during the quarter, compared to analysts’ expectations of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The company’s quarterly revenue was up 52.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.27) EPS. Analysts anticipate that Insmed will post -4.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $158.93, for a total value of $1,700,392.07. Following the completion of the sale, the chief executive officer owned 306,891 shares of the company’s stock, valued at $48,774,186.63. The trade was a 3.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael Alexander Smith sold 1,053 shares of the firm’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $174.17, for a total value of $183,401.01. Following the completion of the sale, the insider directly owned 57,037 shares in the company, valued at approximately $9,934,134.29. The trade was a 1.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 296,799 shares of company stock worth $54,296,286 over the last ninety days. Company insiders own 3.00% of the company’s stock.

Institutional Trading of Insmed

A number of institutional investors and hedge funds have recently made changes to their positions in the company. CIBC Private Wealth Group LLC raised its position in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the period. CoreCap Advisors LLC purchased a new position in shares of Insmed in the 4th quarter worth about $27,000. Hilltop National Bank acquired a new position in shares of Insmed in the 2nd quarter valued at about $28,000. Stone House Investment Management LLC acquired a new position in shares of Insmed in the 3rd quarter valued at about $29,000. Finally, SBI Securities Co. Ltd. grew its holdings in shares of Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 166 shares during the period.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.